The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

How TIME and Statista Determined the World's Most Sustainable Companies of 2025 In the fight against climate change, ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. | Nektar Therapeutics is enjoying the sweet taste of clinical trial success after ...

Nektar Therapeutics said on Tuesday its experimental eczema drug had met the main goal of a mid-stage study, sending its shares up by more than 140% in premarket trading.In the 393-patient trial, drug ...

The agency said it will evaluate whether further regulatory action is needed after investigating the deaths of two patients ...

More than 50 insurers have pledged to streamline and simplify the prior authorization process through six new commitments.

The 2025 report highlights China’s rapid biopharma rise, along with steady global growth and booming biologics   LONDON – 24 June 2025 – Evaluate, the leading provider of market insights for the ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...